Markets

Is a Surprise Coming for Intellia Therapeutics (NTLA)This Earnings Season?

An image of a pen on a stock chart
Credit: Shutterstock photo

Investors are always looking for stocks that are poised to beat at earnings season and Intellia Therapeutics Inc.NTLA may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Intellia Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for NTLA in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 46 cents per share for NTLA, compared to a broader Zacks Consensus Estimate of a loss of 48 cents per share. This suggests that analysts have very recently bumped up their estimates for NTLA, giving the stock a Zacks Earnings ESP of +3.16% heading into earnings season.

Intellia Therapeutics, Inc. Price and EPS Surprise

Intellia Therapeutics, Inc. Price and EPS Surprise | Intellia Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).

Given that NTLA has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Clearly, recent earnings estimate revisions suggest that good things are ahead for Intellia Therapeutics, and that a beat might be in the cards for the upcoming report.

Don't Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks' has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NTLA

Other Topics

Earnings Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More